Maxwell O. Mendes

Maxwell O. Mendes

Auto-generated profile, based on publicly available information

Maxwell O. Mendes

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Brasil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JBJose Diego Brito-Sousa
Jose Diego Brito-Sousa
FMFelipe Murta
Felipe Murta
SVSheila Vitor-Silva
Sheila Vitor-Silva
VSVANDERSON SOUZA SAMPAIO
VANDERSON SOUZA SAMPAIO
MMMaxwell O. Mendes
Maxwell O. Mendes
MLMarcus Vinícius Guimarães de Lacerda
Marcus Vinícius Guimarães de Lacerda
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency greatly hinders Plasmodium vivax malaria radical cure and further elimination due to 8-aminoquinolines-associated hemolysis. Although the deleterious health effects of primaquine in G6PD deficient individuals have been known for over 50 years, G6PD testing is not routinely performed before primaquine treatment in most P. vivax endemic areas. Method/Principal findings: The qualitative CareStart G6PD screening test was implemented in 12 malaria treatment units (MTUs) in the municipality of Rio Preto da Eva, Western Brazilian Amazon, a malaria endemic area, between February 2019 and early January 2020. Training materials were developed and validated; evaluations were conducted on the effectiveness of training health care professionals (HCPs) to perform the test, the interpretation and reliability of routine testing performed by HCPs, and perceptions of HCPs and patients. Most HCPs were unaware of G6PD deficiency and primaquine-related adverse effects. Most of 110 HCPs trained (86/110, 78%) were able to correctly perform the G6PD test after a single 4-hour training session. The test performed by HCPs during implementation showed 100.0% (4/4) sensitivity and 68.1% (62/91) specificity in identifying G6PD deficient patients as compared to a point-of-care quantitative test (Standard G6PD). Conclusions/Significance: G6PD screening using the qualitative CareStart G6PD test performed by HCPs in MTUs of an endemic area showed high sensitivity and concerning low specificity. The amount of false G6PD deficiency detected led to substantial loss of opportunities for radical cure.

1 January 2022 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
JBJose Diego Brito-Sousa
Jose Diego Brito-Sousa
JPJeffe Phanor
Jeffe Phanor
PBPatricia Carvalho da Silva Balieiro
Patricia Carvalho da Silva Balieiro
ASAlexandre Vilhena Silva-Neto
Alexandre Vilhena Silva-Neto
JCJady Shayenne Mota Cordeiro
Jady Shayenne Mota Cordeiro
Wuelton MonteiroWuelton Monteiro
Wuelton Monteiro
Although primaquine (PQ) is indicated for G6PD-deficient patients, data on weekly PQ use in Brazil are limited. We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020. Patients receiving weekly PQ treatment had a lower risk of recurrence than those receiving daily PQ treatment (risk ratio: 0.62, 95% confidence interval: 0.41-0.94), using a model adjusted for study site. Weekly PQ use did not increase the risk of malaria recurrence. Further studies with larger populations are warranted.